Christopher Treleaven

Christopher Treleaven is an experienced professional in operations and project management, particularly within the realms of nonclinical development and toxicology for gene therapy programs. Currently serving as Associate Director of Operations and Project Management at Voyager Therapeutics, Inc., responsibilities include assisting nonclinical toxicology strategies and executing GLP-compliant studies. Previously, as Associate Director at AVROBIO, Christopher directed preclinical safety activities and developed regulatory strategies for clinical trials. Having held foundational roles at bluebird bio and Sarepta Therapeutics, Christopher managed vivarium operations and collaborated on significant research initiatives related to gene editing and immuno-oncology. Christopher's career commenced at Genzyme, contributing to the development of gene therapy strategies for neurodegenerative diseases. Educational qualifications include a Bachelor’s Degree in Business Management from the University of Phoenix and an Associate of Science in Biology from Thomas Nelson Community College.